Travere Therapeutics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023
For the year, the company expects net product sales from continuing operations to be approximately $128 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.6 USD | -3.23% | +7.14% | -26.59% |
1st Jan change | Capi. | |
---|---|---|
-26.59% | 502M | |
+2.97% | 108B | |
+10.21% | 104B | |
+1.57% | 22.33B | |
-12.77% | 22.19B | |
-7.05% | 18.69B | |
-37.64% | 17.74B | |
-6.50% | 17.64B | |
+6.00% | 14.05B | |
+37.20% | 12.51B |